A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-10-29
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2
dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK)
profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in
participants with advanced solid tumors.